
Sinan Guloksuz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5566769/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	13.7	929
2	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. JAMA Psychiatry, 2018, 75, 555.	6.0	516
3	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	2.3	229
4	The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Medicine, 2018, 48, 229-244.	2.7	216
5	A critique of the "ultraâ€high risk―and "transition―paradigm. World Psychiatry, 2017, 16, 200-206.	4.8	206
6	The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry, 2021, 20, 4-33.	4.8	153
7	The evidenceâ€based groupâ€level symptomâ€reduction model as the organizing principle for mental health care: time for change?. World Psychiatry, 2019, 18, 88-96.	4.8	137
8	The experience sampling method as an mHealth tool to support self-monitoring, self-insight, and personalized health care in clinical practice. Depression and Anxiety, 2017, 34, 481-493.	2.0	135
9	A Network Approach to Environmental Impact in Psychotic Disorder: Brief Theoretical Framework. Schizophrenia Bulletin, 2016, 42, 870-873.	2.3	128
10	Antipsychoticâ€induced weight gain in firstâ€episode psychosis patients: a metaâ€analysis of differential effects of antipsychotic medications. Microbial Biotechnology, 2016, 10, 193-202.	0.9	128
11	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry, 2019, 18, 173-182.	4.8	127
12	Cytokine levels in euthymic bipolar patients. Journal of Affective Disorders, 2010, 126, 458-462.	2.0	90
13	Application of network methods for understanding mental disorders: pitfalls and promise. Psychological Medicine, 2017, 47, 2743-2752.	2.7	83
14	Evidence that the presence of psychosis in non-psychotic disorder is environment-dependent and mediated by severity of non-psychotic psychopathology. Psychological Medicine, 2015, 45, 2389-2401.	2.7	72
15	The Exposome Paradigm and the Complexities of Environmental Research in Psychiatry. JAMA Psychiatry, 2018, 75, 985.	6.0	72
16	The Link Between the Immune System, Environment, and Psychosis. Schizophrenia Bulletin, 2017, 43, 693-697.	2.3	66
17	Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience. Psychological Medicine, 2017, 47, 2421-2437.	2.7	63
18	The Immune System and Electroconvulsive Therapy for Depression. Journal of ECT, 2014, 30, 132-137.	0.3	62

#	Article	IF	CITATIONS
19	Evidence That Environmental and Familial Risks for Psychosis Additively Impact a Multidimensional Subthreshold Psychosis Syndrome. Schizophrenia Bulletin, 2018, 44, 710-719.	2.3	59
20	Association of preceding psychosis risk states and nonâ€psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESISâ€2 cohort. World Psychiatry, 2020, 19, 199-205.	4.8	53
21	The impact of electroconvulsive therapy on the tryptophan–kynurenine metabolic pathway. Brain, Behavior, and Immunity, 2015, 48, 48-52.	2.0	52
22	The Complexities of Evaluating the Exposome in Psychiatry: A Data-Driven Illustration of Challenges and Some Propositions for Amendments. Schizophrenia Bulletin, 2018, 44, 1175-1179.	2.3	52
23	Toward incorporating genetic risk scores into symptom networks of psychosis. Psychological Medicine, 2020, 50, 636-643.	2.7	51
24	The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial. Schizophrenia Research, 2014, 160, 180-185.	1.1	50
25	DNA Methylation in Schizophrenia. Advances in Experimental Medicine and Biology, 2017, 978, 211-236.	0.8	49
26	Elevated plasma concentrations of S100 calcium-binding protein B and tumor necrosis factor alpha in children with autism spectrum disorders. Revista Brasileira De Psiquiatria, 2017, 39, 195-200.	0.9	47
27	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. Schizophrenia Bulletin, 2019, 45, 960-965.	2.3	46
28	Evidence for an association between tumor necrosis factor-alpha levels and lithium response. Journal of Affective Disorders, 2012, 143, 148-152.	2.0	44
29	Association of Recent Stressful Life Events With Mental and Physical Health in the Context of Genomic and Exposomic Liability for Schizophrenia. JAMA Psychiatry, 2020, 77, 1296.	6.0	43
30	Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability. PLoS ONE, 2013, 8, e60435.	1.1	39
31	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. Epidemiology and Psychiatric Sciences, 2020, 29, e182.	1.8	36
32	Early intervention service systems for youth mental health: integrating pluripotentiality, clinical staging, and transdiagnostic lessons from early psychosis. Lancet Psychiatry,the, 2022, 9, 413-422.	3.7	36
33	Associations between psychiatric disorders, COVID-19 testing probability and COVID-19 testing results: findings from a population-based study. BJPsych Open, 2020, 6, e87.	0.3	35
34	Clinical Features of Night Eating Syndrome among Depressed Patients. European Eating Disorders Review, 2014, 22, 102-108.	2.3	32
35	Polygenic liability for schizophrenia and childhood adversity influences dailyâ€life emotion dysregulation and psychosis proneness. Acta Psychiatrica Scandinavica, 2020, 141, 465-475.	2.2	31
36	Interaction between environmental and familial affective risk impacts psychosis admixture in states of affective dysregulation. Psychological Medicine, 2019, 49, 1879-1889.	2.7	30

#	Article	IF	CITATIONS
37	Training and practice of psychotherapy in Europe: results of a survey. World Psychiatry, 2011, 10, 238-238.	4.8	29
38	Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?. BMC Psychiatry, 2012, 12, 27.	1.1	29
39	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine, 2020, 50, 1884-1897.	2.7	28
40	Meta-analysis of auditory P50 sensory gating in schizophrenia and bipolar disorder. Psychiatry Research - Neuroimaging, 2020, 300, 111078.	0.9	27
41	Reduced regulatory T cells with increased proinflammatory response in patients with schizophrenia. Psychopharmacology, 2020, 237, 1861-1871.	1.5	27
42	White noise speech illusion and psychosis expression: An experimental investigation of psychosis liability. PLoS ONE, 2017, 12, e0183695.	1.1	26
43	Schizophrenia and the Environment: Within-Person Analyses May be Required to Yield Evidence of Unconfounded and Causal Association—The Example of Cannabis and Psychosis. Schizophrenia Bulletin, 2021, 47, 594-603.	2.3	26
44	Resilience Against Traumatic Stress: Current Developments and Future Directions. Frontiers in Psychiatry, 2018, 9, 676.	1.3	25
45	Recurrent Neural Networks in Mobile Sampling and Intervention. Schizophrenia Bulletin, 2019, 45, 272-276.	2.3	25
46	Analysis of GWAS-Derived Schizophrenia Genes for Links to Ischemia-Hypoxia Response of the Brain. Frontiers in Psychiatry, 2020, 11, 393.	1.3	25
47	Need for Ethnic and Population Diversity in Psychosis Research. Schizophrenia Bulletin, 2021, 47, 889-895.	2.3	25
48	Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry, 2012, 12, 158.	1.1	24
49	Network Approach to Understanding Emotion Dynamics in Relation to Childhood Trauma and Genetic Liability to Psychopathology: Replication of a Prospective Experience Sampling Analysis. Frontiers in Psychology, 2017, 8, 1908.	1.1	24
50	Decreased mitochondrial electron transport proteins and increased complement mediators in plasma neural-derived exosomes of early psychosis. Translational Psychiatry, 2020, 10, 361.	2.4	24
51	Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. PLoS ONE, 2021, 16, e0244944.	1.1	24
52	Association Between Discrimination Stress and Suicidality in Preadolescent Children. Journal of the American Academy of Child and Adolescent Psychiatry, 2022, 61, 686-697.	0.3	24
53	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	4.1	23
54	Do Current Measures of Polygenic Risk for Mental Disorders Contribute to Population Variance in Mental Health?. Schizophrenia Bulletin, 2020, 46, 1353-1362.	2.3	22

#	Article	IF	CITATIONS
55	Neural cellâ€derived plasma exosome protein abnormalities implicate mitochondrial impairment in first episodes of psychosis. FASEB Journal, 2021, 35, e21339.	0.2	22
56	Reducing the Duration of Untreated Psychosis (DUP) in a US Community: A Quasi-Experimental Trial. Schizophrenia Bulletin Open, 2022, 3, sgab057.	0.9	22
57	Exposure to environmental factors increases connectivity between symptom domains in the psychopathology network. BMC Psychiatry, 2016, 16, 223.	1.1	20
58	Electrocardiography changes in bipolar patients during long-term lithium monotherapy. General Hospital Psychiatry, 2014, 36, 694-697.	1.2	18
59	Involvement of hemoglobins in the pathophysiology of Alzheimer's disease. Experimental Gerontology, 2019, 126, 110680.	1.2	18
60	Reasoning bias, working memory performance and a transdiagnostic phenotype of affective disturbances and psychotic experiences in the general population. Psychological Medicine, 2019, 49, 1799-1809.	2.7	18
61	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Psychiatry, 2021, 64, e25.	0.1	18
62	First help-seeking attempt before and after psychosis onset: measures of delay and aversive pathways to care. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 1359-1369.	1.6	18
63	Predictive Performance of Exposome Score for Schizophrenia in the General Population. Schizophrenia Bulletin, 2021, 47, 277-283.	2.3	18
64	Hemoglobins as new players in multiple sclerosis: metabolic and immune aspects. Metabolic Brain Disease, 2016, 31, 983-992.	1.4	17
65	Identifying psychosis spectrum disorder from experience sampling data using machine learning approaches. Schizophrenia Research, 2019, 209, 156-163.	1.1	17
66	Psychometric liability to psychosis and childhood adversities are associated with shorter telomere length: A study on schizophrenia patients, unaffected siblings, and non-clinical controls. Journal of Psychiatric Research, 2019, 111, 169-185.	1.5	17
67	Estimating Aggregate Environmental Risk Score in Psychiatry: The Exposome Score for Schizophrenia. Frontiers in Psychiatry, 2021, 12, 671334.	1.3	17
68	Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry, 2013, 13, 176.	1.1	16
69	Need for evidence-based early intervention programmes: a public health perspective. Evidence-Based Mental Health, 2018, 21, 128-130.	2.2	16
70	Renaming schizophrenia: 5 \tilde{A} — 5. Epidemiology and Psychiatric Sciences, 2019, 28, 254-257.	1.8	16
71	Gender differences in the association between environment and psychosis. Schizophrenia Research, 2022, 243, 120-137.	1.1	16
72	Parsing the impact of early detection on duration of untreated psychosis (DUP): Applying quantile regression to data from the Scandinavian TIPS study. Schizophrenia Research, 2019, 210, 128-134.	1.1	15

#	Article	IF	CITATIONS
73	Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia. Metabolic Brain Disease, 2019, 34, 865-874.	1.4	15
74	Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia. Journal of Clinical Psychopharmacology, 2019, 39, 182-184.	0.7	15
75	Genetic Risk for Smoking: Disentangling Interplay Between Genes and Socioeconomic Status. Behavior Genetics, 2022, 52, 92-107.	1.4	15
76	Equal access for all? Access to medical information for European psychiatric trainees. Psychiatry Research, 2016, 238, 150-152.	1.7	14
77	The NF-κB signaling pathway: an important therapeutic target in psychiatric disorders. Molecular Psychiatry, 2018, 23, 490-491.	4.1	14
78	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine, 2022, 52, 1910-1922.	2.7	14
79	Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1Î ² levels in patients with schizophrenia spectrum disorder and their siblings. Schizophrenia Research, 2021, 229, 27-37.	1.1	14
80	Impact of the first COVID-19 outbreak on mental health service utilisation at a Dutch mental health centre: retrospective observational study. BJPsych Open, 2021, 7, e213.	0.3	14
81	Metabolic syndrome prevalence in different affective temperament profiles in bipolar-I disorder. Revista Brasileira De Psiquiatria, 2013, 35, 131-135.	0.9	13
82	Mobility trends of psychiatric trainees in Turkey: hard to leave, harder to stay?. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 367-369.	1.8	13
83	Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis. Psychological Medicine, 2023, 53, 2317-2327.	2.7	13
84	Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review. Frontiers in Psychiatry, 2021, 12, 625935.	1.3	12
85	Estimating the Association Between Exposome and Psychosis as Well as General Psychopathology: Results From the ABCD Study. Biological Psychiatry Global Open Science, 2022, 2, 283-291.	1.0	12
86	Minor hemoglobins HbA2 and HbF associate with disease severity in bipolar disorder with a likely protective role of HbA2 against post-partum episodes. Journal of Affective Disorders, 2013, 151, 405-408.	2.0	11
87	Predicting Psychosis Using the Experience Sampling Method with Mobile Apps. , 2017, , .		11
88	TwinssCan — Gene-Environment Interaction in Psychotic and Depressive Intermediate Phenotypes: Risk and Protective Factors in a General Population Twin Sample. Twin Research and Human Genetics, 2019, 22, 460-466.	0.3	11
89	What makes the psychosis â€~clinical high risk' state risky: psychosis itself or the co-presence of a non-psychotic disorder?. Epidemiology and Psychiatric Sciences, 2021, 30, e53.	1.8	11
90	Interrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness. Biological Psychiatry, 2022, 91, 531-539.	0.7	11

#	Article	IF	CITATIONS
91	Analyzing the Duration of Untreated Psychosis. JAMA Psychiatry, 2016, 73, 1094.	6.0	10
92	Organization framework and preliminary findings from the Athens Firstâ€Episode Psychosis Research Study. Microbial Biotechnology, 2020, 14, 343-355.	0.9	10
93	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. Psychological Medicine, 2022, 52, 1777-1783.	2.7	10
94	Emotion regulation in response to daily negative and positive events in youth: The role of event intensity and psychopathology. Behaviour Research and Therapy, 2021, 144, 103916.	1.6	10
95	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110440.	2.5	10
96	Schizophrenia as a symptom of psychiatry's reluctance to enter the moral era of medicine. Schizophrenia Research, 2022, 242, 138-140.	1.1	10
97	Temperament characteristics in patients with panic disorder and their first-degree relatives. Comprehensive Psychiatry, 2015, 60, 73-77.	1.5	9
98	A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). Journal of Psychopharmacology, 2020, 34, 524-531.	2.0	9
99	Association between exposome score for schizophrenia and functioning in first-episode psychosis: results from the Athens first-episode psychosis research study. Psychological Medicine, 2023, 53, 2609-2618.	2.7	9
100	Evidence for interaction between genetic liability and childhood trauma in the development of psychotic symptoms. Social Psychiatry and Psychiatric Epidemiology, 2019, 54, 1045-1054.	1.6	8
101	Antipsychotic Exposure in Pregnancy and the Risk of Gestational Diabetes: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2019, 46, 311-318.	2.3	8
102	The jumping to conclusions reasoning bias as a cognitive factor contributing to psychosis progression and persistence: findings from NEMESIS-2. Psychological Medicine, 2021, 51, 1696-1703.	2.7	8
103	Context <i>v.</i> algorithm: evidence that a transdiagnostic framework of contextual clinical characterization is of more clinical value than categorical diagnosis. Psychological Medicine, 2023, 53, 1825-1833.	2.7	8
104	Phenome-wide and genome-wide analyses of quality of life in schizophrenia. BJPsych Open, 2021, 7, e13.	0.3	7
105	The Exposome Paradigm to Understand the Environmental Origins of Mental Disorders. , 2021, 22, 171-176.		7
106	Immunomodifying and neuroprotective effects of noscapine: Implications for multiple sclerosis, neurodegenerative, and psychiatric disorders. Chemico-Biological Interactions, 2022, 352, 109794.	1.7	7
107	Exposome and Trans-syndromal Developmental Trajectories Toward Psychosis. Biological Psychiatry Global Open Science, 2022, 2, 197-205.	1.0	7
108	Phenotypic factors associated with amisulprideâ€induced weight gain in firstâ€episode psychosis patients (from the OPT iMi SE cohort). Acta Psychiatrica Scandinavica, 2019, 140, 283-290.	2.2	6

#	Article	IF	CITATIONS
109	Dr. Strangelove, or how we learned to stop worrying and love uncertainty. World Psychiatry, 2020, 19, 395-396.	4.8	6
110	Natural History, Not Lead Time. American Journal of Psychiatry, 2020, 177, 1185-1185.	4.0	6
111	En attendant Godot: Waiting for the Funeral of "Schizophrenia―and the Baby Shower of the Psychosis Spectrum. Frontiers in Psychiatry, 2021, 12, 618842.	1.3	6
112	Longitudinal associations between alcohol use, smoking, genetic risk scoring and symptoms of depression in the general population: a prospective 6-year cohort study. Psychological Medicine, 2023, 53, 1409-1417.	2.7	6
113	Thiol/Disulfide Homeostasis in Bipolar and Unipolar Depression. Clinical Psychopharmacology and Neuroscience, 2020, 18, 395-401.	0.9	6
114	Association Between Discrimination Stress and Suicidality in Preadolescent Children. Focus (American Psychiatric Publishing), 2022, 20, 252-262.	0.4	6
115	Reversible ptosis probably related to duloxetine use. General Hospital Psychiatry, 2012, 34, e9-e10.	1.2	5
116	Genetic and Environmental Influences on the Affective Regulation Network: A Prospective Experience Sampling Analysis. Frontiers in Psychiatry, 2018, 9, 602.	1.3	5
117	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. Frontiers in Psychiatry, 2019, 10, 676.	1.3	5
118	Evidence for an interrelated cluster of Hallucinatory experiences in the general population: an incidence study. Psychological Medicine, 2020, , 1-10.	2.7	5
119	Be(com)ing social: Daily-life social interactions and parental bonding Developmental Psychology, 2022, 58, 792-805.	1.2	5
120	General psychopathology and its social correlates in the daily lives of youth. Journal of Affective Disorders, 2022, 309, 428-436.	2.0	4
121	Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia. Psychopharmacology, 2018, 235, 1029-1039.	1.5	3
122	Minor Physical Anomalies in Bipolar Disorder. Comprehensive Psychiatry, 2020, 103, 152206.	1.5	3
123	Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial. BMC Psychiatry, 2021, 21, 4.	1.1	3
124	Examining the Independent and Joint Effects of Genomic and Exposomic Liabilities for Schizophrenia Across the Psychosis Spectrum. Biological Psychiatry, 2021, 89, S330-S331.	0.7	2
125	FFECTIVE TEMPERAMENT AND SEASONALITY IN BIPOLAR DISORDER. Psychiatria Danubina, 2019, 31, 106-110.	0.2	2
126	SCIENCE, PSYCHIATRY, AND THE DSM. Turk Psikiyatri Dergisi, 2013, , .	0.2	2

#	Article	IF	CITATIONS
127	A case of oxybutynin dependency. General Hospital Psychiatry, 2010, 32, e5-e6.	1.2	1
128	Seasonal variation of metabolic syndrome prevalence in bipolar disorder. Journal of Mood Disorders, 2012, 2, 51.	0.1	1
129	Authors' reply: Psychosis Spectrum Disorder is a clinical diagnosis. Psychological Medicine, 2018, 48, 523-524.	2.7	1
130	7.3 POLYGENIC RISK FOR SCHIZOPHRENIA MODERATES THE INFLUENCE OF CHILDHOOD ADVERSITY ON DAILY-LIFE EMOTIONAL DYSREGULATION AND PSYCHOSIS PRONENESS. Schizophrenia Bulletin, 2019, 45, S98-S98.	2.3	1
131	What is the role of personal characteristics of psychiatric trainees in Turkey on their mobility and migration?. Asian Journal of Psychiatry, 2019, 42, 30-31.	0.9	1
132	M126. THE MAIN AND INTERACTIVE EFFECTS OF ADULT STRESSFUL LIFE EVENTS WITH GENOMIC AND EXPOSOMIC LIABILITY FOR SCHIZOPHRENIA ON MENTAL AND PHYSICAL HEALTH: A PROSPECTIVE COHORT STUDY. Schizophrenia Bulletin, 2020, 46, S183-S183.	2.3	1
133	O1.2. REDUCING THE DURATION OF UNTREATED PSYCHOSIS IN A U.S. CATCHMENT: THE MINDMAP CAMPAIGN. Schizophrenia Bulletin, 2020, 46, S1-S1.	2.3	1
134	Early Interventions in High Risk Groups for Psychotic Disorders. Noropsikiyatri Arsivi, 2021, 58, S7-S11.	0.2	1
135	Quantiferon-tb Gold Test May Be More Advantageous Than Tuberculin Skin Test For Screening Latent Tuberculosis Infection In Psychiatry Clinics. Medical Journal of the Trakya University, 2010, , .	0.0	0
136	Kraepelin bugün yaşasaydı dikotomi varlığını sürdürdüyor olur muydu? / If Kraepelin was still al dichotomy still survive?. Dusunen Adam, 2011, , 321-330.	ive would 0.0	0
137	Evaluation of antidepressant choices for the treatment of depressive symptoms in patients with bipolar disorder / İki uçlu bozukluğu olan hastalarda depresif belirtilerin tedavisinde antidepresan tercihlerinin deÄŸerlendirilmesi. Dusunen Adam, 2012, , 151-156.	0.0	0
138	O4.4. DOES POLYGENIC RISK SCORE FOR SCHIZOPHRENIA MODERATE THE MOMENTARY AFFECTIVE AND PSYCHOTIC REACTIONS TO DAILY-LIFE STRESSORS?. Schizophrenia Bulletin, 2018, 44, S84-S84.	2.3	0
139	F136. PARSING DUP TO REFINE EARLY DETECTION: QUANTILE REGRESSION OF RESULTS FROM THE SCANDINAVIAN TIPS STUDY. Schizophrenia Bulletin, 2018, 44, S272-S273.	2.3	0
140	T115. REASONING BIAS, WORKING MEMORY PERFORMANCE, AND A TRANSDIAGNOSTIC PHENOTYPE OF AFFECTIVE DISTURBANCES AND PSYCHOTIC EXPERIENCES IN THE GENERAL POPULATION. Schizophrenia Bulletin, 2018, 44, S160-S161.	2.3	0
141	F215. Gene- and Pathway-Based Analysis of the Ischemia-Hypoxia Response to Developmental Adversities: Testing the Developmental Origins of Health and Disease (DOHaD) Model in Mental Health. Biological Psychiatry, 2018, 83, S322-S323.	0.7	0
142	S254. IMPLEMENTATION OF A PROGRAM FOR EARLY INTERVENTION IN PSYCHOSIS ONSET: THE EXPERIENCE OF REGIONE EMILIA ROMAGNA, NORTHERN ITALY. Schizophrenia Bulletin, 2018, 44, S426-S427.	2.3	0
143	S94. MUTATION-INTOLERANT GENES AND MONOGENIC DISEASE GENES IN 145 LOCI OF SCHIZOPHRENIA (SCZ) GWAS ARE LINKED TO THE ISCHEMIA-HYPOXIA RESPONSE. Schizophrenia Bulletin, 2019, 45, S342-S343.	2.3	0
144	O6.7. TESTING THE HIGH RISK AND TRANSITION FRAMEWORK IN THE GENERAL POPULATION: POPULATION-BASED MEASURES OF RISK AND TRANSITION FOR PSYCHOSIS 6-YEAR LONGITUDINAL FOLLOW-UP. Schizophrenia Bulletin, 2019, 45, S178-S178.	2.3	0

#	Article	IF	CITATIONS
145	20.4 EXAMINING THE ASSOCIATION BETWEEN CANNABIS USE AND PSYCHOSIS ACROSS THE SPECTRA OF EXPOSURE AND PHENOTYPE. Schizophrenia Bulletin, 2019, 45, S122-S123.	2.3	Ο
146	T168. Phenome-Wide and Genome-Wide Analyses of Quality of Life in Patients With Psychosis. Biological Psychiatry, 2019, 85, S194.	0.7	0
147	T242. THE TIMING OF FIRST HELP-SEEKING ATTEMPT IN FIRST EPISODE PSYCHOSIS CAN LEAD TO AVERSIVE PATHWAYS TO CARE. RESULTS FROM THE STEP-ED STUDY. Schizophrenia Bulletin, 2020, 46, S324-S325.	2.3	Ο
148	S115. EVALUATION OF THE CLINICAL UTILITY OF SYMPTOM DIMENSIONS ON LONG-TERM CLINICAL AND FUNCTIONAL OUTCOMES IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin, 2020, 46, S78-S78.	2.3	0
149	Interaction Between Polygenic Liability for Schizophrenia and Childhood Adversity Influences Daily-Life Emotional Dysregulation and Psychosis Proneness. Biological Psychiatry, 2020, 87, S1-S2.	0.7	Ο
150	TREATMENT OF BIPOLAR DISORDER IN PREGNANCY AND POSTPARTUM PERIOD. Turk Psikiyatri Dergisi, 2010,	0.2	0
151	Does follow-up in a specialized center influence symptom profile and severity of bipolar depression?. Dusunen Adam, 2010, , 13-17.	0.0	0
152	Evaluation of The Association Between Lithium Treatment and GSK3ß Polymorphism in Bipolar Disorder Patients. Turk Psikiyatri Dergisi, 2017, , .	0.2	0
153	Decreased levels of fasting serum leptin in patients with schizophrenia: a case-control study. Psychiatry and Behavioral Sciences, 2020, , 1.	0.1	0
154	Resilience in psychosis spectrum disorder. , 2020, , 476-484.		0
155	Dimensional conceptualization of psychosis. , 2020, , 21-26.		0
156	Editorial: Gone to Pot: Examining the Association Between Cannabis Use and Medical/Psychiatric Disorders. Frontiers in Psychiatry, 2022, 13, 837757.	1.3	0
157	Corrigendum to: Reducing the Duration of Untreated Psychosis (DUP) in a US Community: A Quasi-Experimental Trial. Schizophrenia Bulletin Open, 2022, 3, .	0.9	0
158	Reducing Delay From Referral to Admission at a U.S. First-Episode Psychosis Service: A Quality Improvement Initiative. Psychiatric Services, 2022, 73, 1416-1419.	1.1	0